These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Inhibitors of anaplastic lymphoma kinase: a patent review. Milkiewicz KL; Ott GR Expert Opin Ther Pat; 2010 Dec; 20(12):1653-81. PubMed ID: 20961208 [TBL] [Abstract][Full Text] [Related]
26. Cancer and kinases: reports from the front line. Burley SK Genome Biol; 2006; 7(4):314. PubMed ID: 16677415 [TBL] [Abstract][Full Text] [Related]
27. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances. Hojjat-Farsangi M J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367 [TBL] [Abstract][Full Text] [Related]
29. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer. Zámečníkova A Expert Opin Drug Discov; 2014 Jan; 9(1):77-92. PubMed ID: 24294890 [TBL] [Abstract][Full Text] [Related]
30. [Consensus on the medical treatment of gastrointestinal stromal tumors]. Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652 [No Abstract] [Full Text] [Related]
31. Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer. Brose MS Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):7-12. PubMed ID: 27168342 [No Abstract] [Full Text] [Related]
32. Chronic myeloid leukemia: Second-line drugs of choice. Gambacorti-Passerini C; Aroldi A; Cordani N; Piazza R Am J Hematol; 2016 Jan; 91(1):67-75. PubMed ID: 26588811 [TBL] [Abstract][Full Text] [Related]
33. The HER3/ErbB3 receptor: a promising target in cancer drug therapy. Desbois-Mouthon C Gastroenterol Clin Biol; 2010; 34(4-5):255-9. PubMed ID: 20418034 [No Abstract] [Full Text] [Related]
34. The era of targeted therapies: increasing role for novel oncologic drugs in dermatology. Montella L; Palmieri G; Lacouture M Arch Dermatol; 2007 Jun; 143(6):788-9. PubMed ID: 17576948 [No Abstract] [Full Text] [Related]
35. Role of tyrosine kinase inhibitors in the management of high-grade gliomas. Ahluwalia MS; Patel M; Peereboom DM Expert Rev Anticancer Ther; 2011 Nov; 11(11):1739-48. PubMed ID: 22050023 [TBL] [Abstract][Full Text] [Related]
36. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer. Shaw AT Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769 [No Abstract] [Full Text] [Related]
37. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases. Chase A; Cross NC Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463 [TBL] [Abstract][Full Text] [Related]
38. Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice? Duong VH; Padron E; List AF; Komrokji RS Expert Rev Hematol; 2013 Oct; 6(5):485-7. PubMed ID: 24083503 [No Abstract] [Full Text] [Related]
39. New tyrosine kinase inhibitors in chronic myeloid leukemia. Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950 [TBL] [Abstract][Full Text] [Related]
40. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Tibes R; Trent J; Kurzrock R Annu Rev Pharmacol Toxicol; 2005; 45():357-84. PubMed ID: 15822181 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]